SAB Biotherapeutics (SABS) Common Equity (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Common Equity data on file, last reported at $227.2 million in Q1 2026.

• Quarterly Common Equity rose 961.54% year-over-year to $227.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $227.2 million (up 961.54% YoY) and the FY2025 annual result came in at $151.5 million, up 483.35% from the prior year.
• Common Equity grew to $227.2 million in Q1 2026, from $151.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $227.2 million in Q1 2026 to a low of $12.0 million in Q2 2025.
• A 5-year average of $58.6 million and a median of $36.9 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2025 — Common Equity sank 73.95% — and 2026, when it surged 961.54%.
• Tracing SABS's Common Equity over 5 years: stood at $31.1 million in 2022, then jumped by 84.49% to $57.3 million in 2023, then sank by 54.68% to $26.0 million in 2024, then surged by 483.35% to $151.5 million in 2025, then surged by 50.0% to $227.2 million in 2026.
• The last three Common Equity figures came in at $227.2 million (Q1 2026), $151.5 million (Q4 2025), and $165.1 million (Q3 2025), per Business Quant data.